• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

    11/10/22 8:00:00 AM ET
    $SBTX
    Specialty Chemicals
    Consumer Discretionary
    Get the next $SBTX alert in real time by email

    Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting

    Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA

    SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of allergic reactions (Type I), including anaphylaxis, will be presented during the 2022 American College of Allergy Asthma and Immunology Annual Scientific Meeting (ACAAI). The meeting is being held November 10-14, 2022, in Louisville, Kentucky.

    Presentations will highlight findings from multiple clinical trials of neffy (EPI-15 and EPI-16) that were included in the company's New Drug Application (NDA) for neffy as an emergency treatment of allergic reactions (Type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). The U.S. Food and Drug Administration (FDA) has accepted the NDA for neffy for review with a Prescription Drug User Fee Act (PDUFA) target action date anticipated in mid-2023.

    Data from the EPI-15 and EPI-16 clinical trials demonstrated that neffy delivered consistent epinephrine levels to attain pharmacokinetic (PK) profile in range of approved intra-muscular (IM) injection products' PK under normal and rhinitis conditions. Additionally, neffy's Pharmacodynamic (PD) profile, the surrogate measure for assessing clinical effectiveness in anaphylaxis (for example, increased blood pressure, heart rate), demonstrated comparable or greater PD response compared with currently approved IM injectable products. These data also provide important insights into the mechanism of action of intranasal epinephrine. ARS will also present findings from a physician/caregiver survey, which suggests that patients and caregivers have a preference for a needle-free epinephrine alternative and would dose neffy sooner in the course of an allergic reaction without the hesitation caused by fear of the needle and pain.

    "We are pleased to share these data from two of our primary clinical trials for neffy, both of which provide critical insights into neffy's potential as the first intranasal medicine for treating severe allergic reactions," said Richard Lowenthal, M.Sc., MSEL, co-founder and chief executive officer of ARS. "Severe allergic reactions can be life-threatening, and today's standard of care is needle-bearing injectable devices associated with numerous administration challenges. The totality of the data generated supports that neffy achieves a PK/PD profile comparable to injectable products, while potentially offering patients a safe, effective and easy to administer, no-needle, no-wait option to approved epinephrine injection devices. With our NDA currently under review by FDA, we are committed to partnering with the Agency and Advocacy groups to ensure we can bring neffy to patients with Type I allergic reactions and their caregivers."

    Details of the presentations are as follows:

    Title: Pharmacokinetics/Pharmacodynamics After Single and Repeat Administration of ARS-1,

    Epinephrine Auto-Injector, and Manual Intramuscular Injection (EPI-15)

    Date & Time: Friday, Nov 11 at 5:30 PM ET

    Session: Other anaphylaxis

    Data Summary: Pharmacokinetic profile following neffy 2.0 mg is within the range of currently approved injection products. neffy's pharmacodynamic profile is comparable to or better than EpiPen or manual injection, suggesting that neffy may be at least as efficacious as these approved products.

    Title: Pharmacokinetics and Pharmacodynamics of ARS-1 and Manual Intramuscular Injection

    in Subjects With/Without Allergic Rhinitis (EPI-16)

    Date & Time: Friday, Nov 11 at 5:00 PM ET

    Session: Other anaphylaxis

    Data Summary: Epinephrine absorption via neffy 2.0 mg under rhinitis resulted in more rapid absorption due to nasal symptoms including mucosal oedema. neffy's pharmacodynamic profile under rhinitis is comparable to manual injection, suggesting that neffy may be at least as efficacious as this approved product.

    Title: Epinephrine Nasal Spray (ARS-1) and Intramuscular Injection:

    Pharmacokinetic/Pharmacodynamic Differences and Differential Affinities for Adrenergic

    Receptors

    Date & Time: Friday, Nov 11 at 5:15 PM ET

    Session : Other anaphylaxis

    Data Summary: neffy 1.0 mg increases systolic blood pressure and heart rate more efficiently than injections, eliciting a comparable pharmacodynamic response at a lower epinephrine concentration that may be attributed to its bypassing of the beta 2-receptors into skeletal muscle in the thigh.

    Title: Time Before Use of Epinephrine Injectable Devices and Triggers Driving Use: A

    Patient/Caregiver Survey

    Date & Time: Friday, Nov 11 at 4:15 PM ET

    Session : Adverse Drug Reactions, Insect Reactions, Anaphylaxis

    Data Summary: The reasons for the delay in use of an epinephrine injectable device had a significant relationship with needle, requirement to go to ER, uncertainty about the symptom being warranted for injection, potential side effects, fear to use, pain, and size of device.

    The results suggest that a device that addresses the reasons for delay and hesitation may help patients and caregivers to use the device without hesitation.

    Title: Epinephrine Via Needle-Free Device Would Be Administered Faster After Symptoms: Results of a Patient/Caregiver Survey

    Date & Time: Friday, Nov 11 at 4:45 PM ET

    Session: Adverse Drug Reactions, Insect Reactions, Anaphylaxis

    Data Summary: A needle-free option for administering epinephrine would be used sooner after symptoms developed and is perceived as being easier to use versus an injectable device. This underscores the need to develop epinephrine modalities utilizing a non-needle-based delivery system.

    About Type I Allergic Reactions including Anaphylaxis

    Type I severe allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 25 to 40 million people in the United States who experience Type I severe allergic reactions. Of those, only 3.3 million currently have an active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.

    About ARS Pharmaceuticals, Inc.

    ARS is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy® (previously referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.

    Statements in this press release that are not purely historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the data to be presented at the ACAAI, and the dates and times of such presentations; the design and potential benefits of neffy®; the anticipated PDUFA target action date; the potential regulatory approval and commercialization of neffy®; the potential market opportunity for neffy®; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipate," "plans," "expects," "will," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the ability to obtain and maintain regulatory approval for neffy®; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from neffy®; the labelling for neffy®, if approved; the scope, progress and expansion of developing and commercializing neffy®; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS's ability to protect its intellectual property position; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" and elsewhere in ARS's most recent filings with the U.S. Securities and Exchange Commission (SEC), including its definitive proxy statement on October 6, 2022, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and any subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at www.sec.gov. These documents can be accessed on ARS's web page at ir.ars-pharma.com by clicking on the link "Financials & Filings."

    The forward-looking statements included in this presentation are made only as of the date hereof. ARS assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

    ARS Media Contacts:

    Caroline Cunningham

    Porter Novelli

    [email protected]

    ARS Investor Contacts:

    Justin Chakma

    ARS Pharmaceuticals

    [email protected]



    Get the next $SBTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBTX

    DatePrice TargetRatingAnalyst
    4/4/2022$25.00 → $3.50Buy → Neutral
    Goldman
    4/1/2022$25.00 → $1.80Outperform → Mkt Perform
    SVB Leerink
    4/1/2022$32.00 → $6.00Buy → Hold
    Stifel
    4/1/2022Buy → Neutral
    H.C. Wainwright
    11/12/2021$42.00 → $25.00Outperform
    SVB Leerink
    8/16/2021$46.00 → $49.00Outperform
    SVB Leerink
    More analyst ratings

    $SBTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lowenthal Richard E gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 20% to 4,126,822 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:53:49 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Karas Eric

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:47:38 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Tanimoto Sarina gifted 2,100,000 shares and received a gift of 2,100,000 shares, decreasing direct ownership by 24% to 3,276,854 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      1/4/24 4:45:07 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

      SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the appointment of Maria Koehler, M.D., Ph.D. to Silverback’s Board of Directors. “On behalf of the board of directors and senior management team at Silverback, I am pleased to welcome Maria to the board,” said Peter Thompson, M.D., Co-founder and Chair of the Silverback Board of Directors. “Maria is an accomplished biopharmaceutical ve

      3/15/21 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

      Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that positive clinical data supporting neffy® (previously referred to as ARS-1), the potential first non-injectable medicine for treatment of alle

      11/10/22 8:00:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

      Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved neffy® NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) (ARS or the Company), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the closing of its merger with Silverback Therapeutics, Inc. (Silverback). This follows the satisfaction of all cus

      11/8/22 4:02:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

      neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs). If approved by the FDA, neffy would be the first non-injectable treatment available to patients with allergic reactions (type I) including anaphylaxis. The FDA has assigned a Prescription Drug U

      10/21/22 7:31:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    SEC Filings

    See more

    $SBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SBTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Silverback Therapeutics Inc.

      10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:04:53 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      11/9/23 4:02:29 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)

      9/25/23 4:17:04 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13G/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      2/9/24 8:35:56 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/25/23 4:30:47 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Silverback Therapeutics Inc. (Amendment)

      SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)

      9/1/23 4:15:58 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Fitzpatrick Alexander A bought $319,954 worth of shares (86,258 units at $3.71), increasing direct ownership by 2,905% to 89,227 units (SEC Form 4)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      10/2/23 4:23:09 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4: Ra Capital Management, L.P. bought $8,183,526 worth of shares (2,700,000 units at $3.03)

      4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

      9/25/23 4:30:22 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Financials

    Live finance-specific insights

    See more
    • Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

      Transaction to support potential commercialization of neffy™, ARS's needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anap

      7/21/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

      - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of 2022 - Silverback to restructure workforce to support prioritized development, reduce operating expense, and extend cash runway - Estimated cash runway extended into the second half of 2026 Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chron

      3/31/22 4:00:00 PM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

      – Proof-of-mechanism established with activation of myeloid and T/NK cells, and evidence of SBT6050 payload localization in the tumor microenvironment – – SBT6050 demonstrated a manageable safety profile with adverse events consistent with on-mechanism immune activation, both as a monotherapy or in combination with pembrolizumab – – Early signals of anti-tumor activity observed in a heavily pre-treated, heterogeneous population – – Management to host conference call today at 6:30 AM ET – Silverback Therapeutics, Inc. (NASDAQ:SBTX) ("Silverback"), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissu

      9/16/21 3:30:00 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary

    $SBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Silverback Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously

      4/4/22 7:33:52 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously

      4/1/22 9:04:51 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary
    • Silverback Therapeutics downgraded by Stifel with a new price target

      Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously

      4/1/22 7:22:09 AM ET
      $SBTX
      Specialty Chemicals
      Consumer Discretionary